Apply for financial support

To find the financial support program that may be right for you, answer a few questions with the financial assistance tool, which will guide you through the application process and any next steps.

Want more information about some of your options?
Take a look at some potential financial support programs.

Here are a few things you may need on hand:

Patient information: full name, date of birth, mailing address, email, phone (home and/or mobile) and insurance information
Prescribing doctor's information: first/last name, practice name, address and phone
Patient's financial eligibility information: number of people in the household (including patient) and annual net household income*

Get started

*not required for all programs

Need more help? Contact Pulmozyme Access Solutions

Call 866-422-2377 (Mon.-Fri., 6AM-5PM PST)

Tips and links for Cystic Fibrosis patients

Tips & Helpful Links

Find information about nutrition, exercise and resources for people living with Cystic Fibrosis.

Explore Tips

Downloadable Resources from Pulmozyme

Get helpful documents and printable PDFs for people taking Pulmozyme.

Download a File

Indication and Usage

Pulmozyme (dornase alfa) is indicated, along with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme along with standard therapies for cystic fibrosis have been established in pediatric patients. The use of Pulmozyme in pediatric patients at 5 to 17 years of age is supported by evidence from a randomized, controlled trial. The use of Pulmozyme in patients less than 5 years of age is supported by the efficacy data from the same randomized, controlled trial and additional safety data in pediatric patients aged 3 months to less than 5 years who received Pulmozyme.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

For further information, please see the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF Care Team.